言语治疗联合脑蛋白水解物促进急性缺血性卒中后非流畅性失语恢复:ESCAS随机先导研究
ESCAS前瞻性随机双盲先导研究在2个罗马尼亚卒中中心纳入左侧大脑中动脉供血区缺血性卒中后3至5天、非流畅性失语患者,比较脑蛋白水解物联合言语治疗与安慰剂联合言语治疗。脑蛋白水解物组第4次访视西方失语症成套测验评分平均增加35.579分,高于安慰剂组的20.774分,两组均值差14.805分(95%CI 9.521-20.089,P<0.001)。作者认为该联合治疗显示出潜力,但需更大样本研究进一步确认疗效。
要点
- 脑蛋白水解物联合言语治疗组西方失语症成套测验评分改善优于安慰剂联合言语治疗组,均值差14.805分(95%CI 9.521-20.089,P<0.001)。
- 脑蛋白水解物组美国国立卫生研究院卒中量表评分下降幅度大于安慰剂组,差值为2.085分(95%CI 1.076-3.094,P<0.001)。
- 安全性分析未提出担忧(发生不良事件的患者数P=0.105,每例患者不良事件数P=0.134)。
核心结论
- 脑蛋白水解物联合言语治疗对卒中后非流畅性失语恢复显示出有希望的潜力。
- 在语言功能和神经功能缺损方面观察到显著改善。
- 需要更大队列的进一步研究来充分确立该联合治疗的疗效。
研究设计与样本
- ESCAS试验为前瞻性、随机对照、双盲研究,在2个罗马尼亚卒中中心开展。
- 纳入左侧大脑中动脉供血区缺血性卒中后3至5天、非流畅性失语、右利手且母语为罗马尼亚语的患者。
- 参与者接受脑蛋白水解物或安慰剂联合言语治疗,以10天为一周期、共3个间隔,分别在基线、30天、60天和90天进行评估。
- 共入组132例患者,意向性分析纳入123例,符合方案分析纳入120例。
主要发现
- 两组在后续访视中西方失语症成套测验和美国国立卫生研究院卒中量表评分较基线均有改善。
- 脑蛋白水解物组第4次访视西方失语症成套测验评分平均增加35.579±16.316分(95%CI 31.289-39.869,P<0.001),安慰剂组为20.774±12.486分(95%CI 17.603-23.945,P<0.001),两组均值差14.805分(95%CI 9.521-20.089,P<0.001)。
- 脑蛋白水解物组美国国立卫生研究院卒中量表评分下降幅度大于安慰剂组,差值为2.085分(95%CI 1.076-3.094,P<0.001)。
- 安全性分析未提出担忧(发生不良事件的患者数P=0.105,每例患者不良事件数P=0.134)。
- 脑蛋白水解物组在功能独立性(巴氏指数)方面改善更大,改良Rankin量表显示残疾减轻趋势。
关键数值与推荐
- 主要结局指标为西方失语症成套测验评估的语言功能,效应估计值为组间均值差。
- 次要结局指标包括美国国立卫生研究院卒中量表(神经功能缺损)、改良Rankin量表(整体残疾)和巴氏指数(日常生活活动能力)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要更大队列的进一步研究来充分确立该联合治疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke-induced aphasia significantly impacts communication and quality of life. Despite the standard treatment being speech and language therapy, outcomes vary, highlighting the need for additional therapies. Cerebrolysin, a neuroprotective and neurotrophic agent, has shown potential in stroke management. This study addresses the notable gap in research about the combined use of Cerebrolysin and speech therapy, evaluating their synergistic potential in the treatment of aphasia. METHODS: The ESCAS trial (The Efficacy and Safety of Cerebrolysin in the Treatment of Aphasia After Acute Ischemic Stroke), a prospective, randomized-controlled, double-blinded study was conducted in 2 Romanian stroke centers. Participants included those with left middle cerebral artery territory ischemic stroke and nonfluent aphasia, enrolled 3 to 5 days poststroke. Inclusion criteria were right-handedness and Romanian as the mother tongue. Participants received Cerebrolysin or a placebo combined with speech and language therapy in 10-day cycles over 3 intervals, and evaluations were done at baseline, 30, 60, and 90 days respectively. The main outcome measure was Western Aphasia Battery for language function. Changes at days 30, 60, and 90 compared with baseline were quantified, and the effect estimand used was the difference in means between groups. Secondary outcome measurements were the National Institutes of Health Stroke Scale for neurological deficit, the modified Rankin Scale for global disability, and the Barthel Index for activities of daily living. RESULTS: Out of 132 enrolled patients, 123 were included in the intention-to-treat analysis, and 120 in the per-protocol analysis. Overall, both groups showed improvement at subsequent visits compared with the baseline for Western Aphasia Battery and the National Institutes of Health Stroke Scale. The Cerebrolysin group showed greater improvements in Western Aphasia Battery (visit 4 mean increase of 35.579±16.316 [95% CI, 31.289-39.869] points; P<0.001) compared with the placebo group (20.774±12.486 [95% CI, 17.603-23.945] points; P<0.001), a difference in means of 14.805 (95% CI, 9.521-20.089) points (P<0.001). The Cerebrolysin group also showed significant improvements (higher decreases) in National Institutes of Health Stroke Scale scores compared with the placebo group (2.085 [95% CI, 1.076-3.094] points; P<0.001). Safety analysis raised no concerns (number of patients with adverse events P=0.105, number of adverse events per patient P=0.134). Additionally, the Cerebrolysin group showed greater improvements in functional independence (Barthel Index) and a trend toward reduced disability (modified Rankin Scale) compared with the placebo group. CONCLUSIONS: Cerebrolysin combined with speech and language therapy offers promising potential for enhancing recovery in poststroke nonfluent aphasia. Significant improvements were observed in language and neurological deficits, underscoring the importance of adjunctive therapies in nonfluent aphasia rehabilitation. Further research with larger cohorts is needed to fully establish the efficacy of this combination therapy. REGISTRATION: URL: https://www.isrctn.com; Unique identifier: ISRCTN54581790.
引用
- Homberg V, Jianu DC, Stan A, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025. PMID: 39957612. doi:10.1161/STROKEAHA.124.049834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。